TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Pre- and Probiotics on P-cresol Plasma Levels in Patients Bearing a Kidney Allograft
Brief Summary: The purpose of this study is to establish whether a short treatment with the synbiotic combination Probinul neutro® may decrease the plasma concentration of the uremic toxin p-cresol in patients bearing a kidney allograft. The effect of this treatment on plasma levels of immunosuppressant drugs will be evaluated as well.


Options:
A: Arm Label: CONTROL; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: CONTROL | Arm Label: SYNBIOTIC; Type: EXPERIMENTAL; Interventions: Dietary Supplement: SYNBIOTIC | Intervention Type: DIETARY_SUPPLEMENT; Name: CONTROL; Assigned to Arm(s): CONTROL | Intervention Type: DIETARY_SUPPLEMENT; Name: SYNBIOTIC; Assigned to Arm(s): SYNBIOTIC
B: Arm Label: I; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: Probiotic Supplement | Intervention Type: DRUG; Name: Probiotic Supplement; Assigned to Arm(s): II | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): I
C: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Control | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): Probiotic

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of the Lab-score on Antibiotic Prescription Rate in Children Aged 7 Days to 3 Years Old With Fever Without Source.
Brief Summary: Detecting serious bacterial infections (SBI) in children presenting to the Pediatric Emergency Department (PED) with fever without source (FWS) is a frequent diagnostic challenge. The recently described Lab-score, based on the combined determination of Procalcitonin, C-Reactive Protein (CRP) and urine dipstick results, has been shown an accurate tool for SBI prediction on retrospective cohorts. The investigators aimed to assess the usefulness of the Lab-score in safely decreasing unnecessary antibiotic prescriptions in children with FWS, and to prospectively determine the diagnostic characteristics of the Lab-score compared to other classically used SBI biomarkers (white blood cell (WBC) count, band count and CRP).


Options:
A: Arm Label: Lab-score group; Type: EXPERIMENTAL; Interventions: Biological: Allocation to the Lab-score group | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Allocation to the control group | Intervention Type: BIOLOGICAL; Name: Allocation to the Lab-score group; Assigned to Arm(s): Lab-score group | Intervention Type: BIOLOGICAL; Name: Allocation to the control group; Assigned to Arm(s): Control group
B: Arm Label: Group 1 - C-reactive protein (CRP) guided ab therapy; Type: EXPERIMENTAL; Interventions: Other: C-reactive protein guided antibiotic therapy | Arm Label: Group 2 - procalcitonin (PCT) guided ab therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Procalcitonin guided antibiotic therapy | Intervention Type: OTHER; Name: C-reactive protein guided antibiotic therapy; Assigned to Arm(s): Group 1 - C-reactive protein (CRP) guided ab therapy | Intervention Type: OTHER; Name: Procalcitonin guided antibiotic therapy; Assigned to Arm(s): Group 2 - procalcitonin (PCT) guided ab therapy
C: Intervention Type: BEHAVIORAL; Name: Quality improvement strategies; Assigned to Arm(s): N/A
D: Arm Label: A; Type: NO_INTERVENTION; Interventions: Behavioral: Academic Detailing by the Antimicrobial Utilization Team (AUT) | Intervention Type: BEHAVIORAL; Name: Academic Detailing by the Antimicrobial Utilization Team (AUT); Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin to Augment Low Milk Supply in Pre-diabetic Mothers, a Phase I/II Randomized Clinical Trial
Brief Summary: Most new mothers in the United States will start off breastfeeding. For some mothers, despite following best practices, they are not able to meet their breastfeeding goals due to unexplained low milk supply. At the same time, nearly 1 in 4 new mothers are pre-diabetic (elevated blood sugar, but not yet diabetic). My progression of research suggests that the same metabolic factors causing pre-diabetes may also be causing low milk supply. Metformin is a widely prescribed drug to treat high blood sugar. This study is a preliminary, small scale randomized trial designed to test for a trend in the hypothesis that metformin is safe and potentially effective in treating low milk supply in insulin resistant and pre-diabetic mothers.


Options:
A: Arm Label: study herbal tea; Type: EXPERIMENTAL; Interventions: Dietary Supplement: study herbal tea | Arm Label: herbal placebo tea; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: herbal placebo tea | Intervention Type: DIETARY_SUPPLEMENT; Name: study herbal tea; Assigned to Arm(s): study herbal tea | Intervention Type: DIETARY_SUPPLEMENT; Name: herbal placebo tea; Assigned to Arm(s): herbal placebo tea
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Herbal galactagogue; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Herbal galactagogue | Intervention Type: DIETARY_SUPPLEMENT; Name: Herbal galactagogue; Assigned to Arm(s): Herbal galactagogue | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Standard care plus metformin; Type: EXPERIMENTAL; Interventions: Behavioral: Standard care, Drug: Metformin | Arm Label: Standard Care plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard care, Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care plus placebo, Standard care plus metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Standard care plus metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard Care plus placebo
D: Arm Label: Fenugreek category 1; Type: EXPERIMENTAL; Interventions: Drug: fenugreek | Arm Label: Placebo Category 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Psyllium) | Intervention Type: DRUG; Name: fenugreek; Assigned to Arm(s): Fenugreek category 1 | Intervention Type: DRUG; Name: Placebo (Psyllium); Assigned to Arm(s): Placebo Category 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Pulmonary Rehabilitation After Exacerbations of Bronchiectasis
Brief Summary: Pulmonary rehabilitation is well established as a treatment in COPD. After exacerbations of COPD, rehabilitation is associated with reduced frequency of exacerbations and improved exercise capacity. No data are available in bronchiectasis.

This study will randomly assign patients with bronchiectasis exacerbations to pulmonary rehabilitation or standard care. The hypothesis is that exercise capacity will be improved by pulmonary rehabilitation at 8 weeks.


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
B: Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary rehabilitation | Intervention Type: PROCEDURE; Name: Pulmonary rehabilitation; Assigned to Arm(s): Pulmonary rehabilitation | Intervention Type: PROCEDURE; Name: Pulmonary rehabilitation; Assigned to Arm(s): Pulmonary rehabilitation
C: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy
D: Arm Label: Training Group; Type: EXPERIMENTAL; Interventions: Other: Training Group | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Group | Intervention Type: OTHER; Name: Training Group; Assigned to Arm(s): Training Group | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implementation of Telemonitoring in the Management of Acute Exacerbations of Chronic Heart Failure and Respiratory Failure/Chronic Obstructive Pulmonary Disease
Brief Summary: The aims of the study are to:

1. Implement a telemonitoring programme in heart failure and obstructive pulmonary disease (COPD) /chronic respiratory patients by assessing the real world impact of on readmissions, consults, home visits, quality of life and economic endpoints.
2. Explore the effects of telemonitoring across heart and respiratory groups with respect to i) factors that influence how patients integrate telemonitoring into their daily routines and self care behaviour and ii) how healthcare professionals use telemonitoring to aid decision- making.
3. Understand the impact of telemonitoring on a variety of care pathways.


Options:
A: Arm Label: Control group (Group A); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Intervention group (Group B); Type: OTHER; Interventions: Other: Home-based telehealth program, Other: Home-based rehabilitation, Other: Usual care | Intervention Type: OTHER; Name: Home-based telehealth program; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Home-based rehabilitation; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control group (Group A), Intervention group (Group B)
B: Arm Label: Activity-Self Management; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management and Motivational Interviewing | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-Management and Motivational Interviewing; Assigned to Arm(s): Activity-Self Management
C: Arm Label: Control period; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: CE marked Philips Motiva system | Intervention Type: DEVICE; Name: CE marked Philips Motiva system; Assigned to Arm(s): Telemonitoring
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implementation of Telemonitoring in the Management of Acute Exacerbations of Chronic Heart Failure and Respiratory Failure/Chronic Obstructive Pulmonary Disease
Brief Summary: The aims of the study are to:

1. Implement a telemonitoring programme in heart failure and obstructive pulmonary disease (COPD) /chronic respiratory patients by assessing the real world impact of on readmissions, consults, home visits, quality of life and economic endpoints.
2. Explore the effects of telemonitoring across heart and respiratory groups with respect to i) factors that influence how patients integrate telemonitoring into their daily routines and self care behaviour and ii) how healthcare professionals use telemonitoring to aid decision- making.
3. Understand the impact of telemonitoring on a variety of care pathways.


Options:
A: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: care at initiative of the patient (usual GP care) | Arm Label: monitoring controls; Type: EXPERIMENTAL; Interventions: Behavioral: regular practice nurse review (monitoring controls) | Arm Label: self-management; Type: EXPERIMENTAL; Interventions: Behavioral: an integrated self-management education program | Intervention Type: BEHAVIORAL; Name: an integrated self-management education program; Assigned to Arm(s): self-management | Intervention Type: BEHAVIORAL; Name: regular practice nurse review (monitoring controls); Assigned to Arm(s): monitoring controls | Intervention Type: BEHAVIORAL; Name: care at initiative of the patient (usual GP care); Assigned to Arm(s): usual care
B: Arm Label: Control period; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemonitoring; Type: EXPERIMENTAL; Interventions: Device: CE marked Philips Motiva system | Intervention Type: DEVICE; Name: CE marked Philips Motiva system; Assigned to Arm(s): Telemonitoring
C: Intervention Type: BEHAVIORAL; Name: Intermediate care package; Assigned to Arm(s): N/A
D: Arm Label: Disease management program; Type: EXPERIMENTAL; Interventions: Other: Disease Management | Arm Label: Usual site management; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual site management | Intervention Type: OTHER; Name: Disease Management; Assigned to Arm(s): Disease management program | Intervention Type: OTHER; Name: Usual site management; Assigned to Arm(s): Usual site management

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis
Brief Summary: The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active psoriatic arthritis (a chronic inflammatory arthritis that is associated with psoriasis).


Options:
A: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.
B: Arm Label: Intensive management; Type: EXPERIMENTAL; Interventions: Drug: Intensive management or Tight control | Arm Label: Standard management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard management - Control group | Intervention Type: DRUG; Name: Intensive management or Tight control; Assigned to Arm(s): Intensive management | Intervention Type: DRUG; Name: Standard management - Control group; Assigned to Arm(s): Standard management
C: Arm Label: Treatment Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Golimumab | Arm Label: Treatment Group 2: Golimumab; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Golimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment Group 1: Placebo, Treatment Group 2: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Treatment Group 1: Placebo, Treatment Group 2: Golimumab
D: Arm Label: 10 mg Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 15 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 20 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 25 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 10 mg Methotrexate (MTX), 15 mg MTX, 20 mg MTX, 25 mg MTX

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Cost-effectiveness of a Multimodal Rehabilitation Programme (MRP) for Adolescents With Chronic Musculoskeletal Pain (12-21 Years) Compared to Care as Usual (CAU); a Randomized Clinical Trial (2B Active)
Brief Summary: The purpose of this study is to evaluate whether a multimodal rehabilitation program effectively reduces functional disability in adolescents with chronic musculoskeletal pain, compared to care as usual.


Options:
A: Arm Label: Education Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Arm Label: Pain Self-Management Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Pain self-management, Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Pain self-management; Assigned to Arm(s): Pain Self-Management Intervention | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education Control, Pain Self-Management Intervention
B: Arm Label: Multimodal Rehabilitation Program; Type: EXPERIMENTAL; Interventions: Behavioral: Multimodal Rehabilitation Program | Arm Label: Care as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care as Usual | Intervention Type: BEHAVIORAL; Name: Multimodal Rehabilitation Program; Assigned to Arm(s): Multimodal Rehabilitation Program | Intervention Type: BEHAVIORAL; Name: Care as Usual; Assigned to Arm(s): Care as Usual
C: Arm Label: Chiropractic + Exercise; Type: EXPERIMENTAL; Interventions: Other: Chiropractic + Exercise | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Chiropractic + Exercise; Assigned to Arm(s): Chiropractic + Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Internet-based JIA Self-Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Teens Taking Charge | Arm Label: Attention Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Management | Intervention Type: BEHAVIORAL; Name: Teens Taking Charge; Assigned to Arm(s): Internet-based JIA Self-Management Program | Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): Attention Control Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Cost-effectiveness of a Multimodal Rehabilitation Programme (MRP) for Adolescents With Chronic Musculoskeletal Pain (12-21 Years) Compared to Care as Usual (CAU); a Randomized Clinical Trial (2B Active)
Brief Summary: The purpose of this study is to evaluate whether a multimodal rehabilitation program effectively reduces functional disability in adolescents with chronic musculoskeletal pain, compared to care as usual.


Options:
A: Arm Label: Chiropractic + Exercise; Type: EXPERIMENTAL; Interventions: Other: Chiropractic + Exercise | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Chiropractic + Exercise; Assigned to Arm(s): Chiropractic + Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
B: Arm Label: Multimodal Rehabilitation Program; Type: EXPERIMENTAL; Interventions: Behavioral: Multimodal Rehabilitation Program | Arm Label: Care as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care as Usual | Intervention Type: BEHAVIORAL; Name: Multimodal Rehabilitation Program; Assigned to Arm(s): Multimodal Rehabilitation Program | Intervention Type: BEHAVIORAL; Name: Care as Usual; Assigned to Arm(s): Care as Usual
C: Arm Label: Mindfulness Group; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Group | Intervention Type: BEHAVIORAL; Name: Mindfulness Group; Assigned to Arm(s): Mindfulness Group
D: Arm Label: Behavioural Intervention/Feedback; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Arm Label: Video Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Video Attention Control | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Behavioural Intervention/Feedback | Intervention Type: OTHER; Name: Video Attention Control; Assigned to Arm(s): Video Attention Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Additional Therapeutic Effects of Virtual Reality System in Children With Developmental Delays
Brief Summary: The purpose of this study is to investigate the effects of virtual reality system on children with developmental delays.


Options:
A: Arm Label: Virtual reality video game; Type: ACTIVE_COMPARATOR; Interventions: Other: virtual reality system | Arm Label: Virtual reality system; Type: PLACEBO_COMPARATOR; Interventions: Other: virtual reality system | Intervention Type: OTHER; Name: virtual reality system; Assigned to Arm(s): Virtual reality system, Virtual reality video game
B: Arm Label: Stabilization Group; Type: EXPERIMENTAL; Interventions: Other: Core Stabilization, Other: Traditional upper extremity rehabilitation | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional upper extremity rehabilitation | Intervention Type: OTHER; Name: Core Stabilization; Assigned to Arm(s): Stabilization Group | Intervention Type: OTHER; Name: Traditional upper extremity rehabilitation; Assigned to Arm(s): Control Group, Stabilization Group
C: Arm Label: Typically Developing Infants; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home Program; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy | Arm Label: Perceptual-motor intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy | Intervention Type: OTHER; Name: Physical therapy; Assigned to Arm(s): Home Program, Perceptual-motor intervention
D: Arm Label: Intervention Stationary Cycling; Type: EXPERIMENTAL; Interventions: Other: Stationary Cycling | Intervention Type: OTHER; Name: Stationary Cycling; Assigned to Arm(s): Intervention Stationary Cycling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Levosimendan Pretreatment in Patients With Low Ejection Fraction (40 % or Less) Undergoing CABG: a Randomised, Double Blind, Multicenter Trial
Brief Summary: The investigators want to test the hypothesis that an infusion of levosimendan started prior to CABG surgery can reduce incidence and severity of low cardiac output syndrome in patients with poor LV function (EF 40% or less).


Options:
A: Arm Label: Levosimendan; Type: EXPERIMENTAL; Interventions: Drug: Levosimendan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): Levosimendan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: L; Type: EXPERIMENTAL; Interventions: Drug: levosimendan | Arm Label: P; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): L | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Levosimendan; Type: EXPERIMENTAL; Interventions: Drug: Levosimendan | Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): Levosimendan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: levosimendan; Type: ACTIVE_COMPARATOR; Interventions: Drug: levosimendan | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): levosimendan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: D